Skip to main content
. 2020 Jan 23;26:100469. doi: 10.1016/j.ijcha.2020.100469

Table 3.

Clinical Outcomes at 12-month follow-up.

N = 259
MACE at 12 months, n, % 10 (4)
CVS mortality, n, % 4 (1.5)
TLR, n, % 4 (1.5)
MI, n, % 5 (2)
Stent thrombosis, n, % 4 (1.5)

MACE: major adverse cardiac event, CVS: cardiovascular, TLR: target lesion revascularization, MI: myocardial infarction.